VYSTAR Corp is a development‐stage biotechnology company that specializes in the research, development and commercialization of proprietary yeast‐derived beta glucan ingredients designed to support human and animal health. The company’s core technology leverages a patented enrichment process that isolates high‐purity beta‐1,3/1,6‐D‐glucan from Saccharomyces cerevisiae cell walls. VYSTAR’s scientific team focuses on identifying novel health benefits associated with its glucan platform, targeting immune support, wound healing and anti‐inflammatory applications.
VYSTAR’s product portfolio includes nutraceutical formulations, functional food and beverage ingredients, animal health supplements and topical skincare applications. The company markets powdered and encapsulated glucan products under various proprietary brands for use in dietary supplements, veterinary feed additives and cosmetic formulations. Through collaborative research agreements with universities and contract manufacturers, VYSTAR continues to expand its pipeline of beta glucan–based solutions aimed at enhancing cellular function and promoting overall wellness.
Headquartered in Tampa, Florida, VYSTAR leverages a network of strategic partnerships and toll‐manufacturing arrangements in Central and South America to scale production of its patented glucan ingredients. The company distributes its products throughout North America, Europe and parts of Asia, working closely with nutraceutical distributors, contract packagers and private‐label customers. VYSTAR’s global footprint is supported by cross‐functional teams in research and development, quality assurance and regulatory affairs, ensuring compliance with international standards for dietary supplements and cosmetic actives.
Originally founded in the mid-1990s under the name YeastTech Innovations, the company rebranded as VYSTAR Corp in 2005 to reflect its expanded focus on advanced glucan technologies. The leadership team is spearheaded by CEO Robert A. Wright, who brings more than two decades of experience in biotech commercialization, alongside Chairman Dr. Henry J. Levy, an immunology expert responsible for guiding the company’s R&D strategy. Under their stewardship, VYSTAR continues to pursue clinical studies and strategic alliances to broaden the applications of its beta glucan platform and drive long-term growth.
AI Generated. May Contain Errors.
